Meanwhile, so far in 2017, the FDA has approved 5 new drugs including Trulance (treatment of chronic idiopathic constipation in adults) and Parsabiv (treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis).ETFs in Focus Highlighted below are some biotech ETFs - ETFs present a low-cost and convenient way to get a diversified exposure to the sector.
Trump made it clear that he does not like what happened to drug prices and he will bring them down.
Drug pricing was not the only issue that impacted the sector last year - 2016 was also disappointing from an R&D perspective with a fewer number drugs managing to gain FDA approval.
Biosimilars are expected to reduce healthcare costs and provide a large number of patients with access to much needed biologic treatments.
Biosimilars are also gaining acceptance across formularies. Licensing agreements and deals including those with opt-in arrangements should continue being signed with immuno-oncology remaining a favorite area.
2011 by Van Eck, tracks the Market Vectors US Listed Biotech 25 Index. The fund's expense ratio is 0.35%, while dividend yield is 0.21%.
The trading volume is roughly 50,198 shares per day.The FDA approved 22 new drugs in 2016 including Exondys 51 (Duchenne muscular dystrophy), Epclusa (hepatitis C virus), Ocaliva (rare, chronic liver disease), Zinbryta (multiple sclerosis), and Venclexta (chronic lymphocytic leukemia in patients with a specific chromosomal abnormality) among others.The agency also expanded the label of cancer drugs like Kyprolis and Imbruvica.i Shares Nasdaq Biotechnology (NASDAQ: IBB) IBB, launched in Feb.2001 by Black Rock Investments LLC, tracks the Nasdaq Biotechnology Index.Moreover, major biotech and pharma companies should gain from Trump's proposed tax plan and proposal to repatriate corporate profits held offshore at a one-time tax rate.